Oregon Public Employees Retirement Fund raised its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 7.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,790 shares of the company’s stock after purchasing an additional 1,000 shares during the quarter. Oregon Public Employees Retirement Fund’s holdings in Amphastar Pharmaceuticals were worth $277,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also made changes to their positions in the business. BNP Paribas Arbitrage SA boosted its stake in Amphastar Pharmaceuticals by 648.1% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 15,875 shares of the company’s stock worth $298,000 after purchasing an additional 13,753 shares during the period. Comerica Bank boosted its stake in Amphastar Pharmaceuticals by 6.8% in the 3rd quarter. Comerica Bank now owns 36,868 shares of the company’s stock worth $768,000 after purchasing an additional 2,335 shares during the period. Exchange Traded Concepts LLC bought a new position in Amphastar Pharmaceuticals in the 3rd quarter worth about $296,000. DekaBank Deutsche Girozentrale bought a new position in Amphastar Pharmaceuticals in the 3rd quarter worth about $274,000. Finally, State of New Jersey Common Pension Fund D boosted its stake in Amphastar Pharmaceuticals by 5.4% in the 3rd quarter. State of New Jersey Common Pension Fund D now owns 111,028 shares of the company’s stock worth $2,082,000 after purchasing an additional 5,738 shares during the period. Hedge funds and other institutional investors own 52.91% of the company’s stock.

AMPH has been the topic of several recent analyst reports. BidaskClub cut Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, November 7th. TheStreet cut Amphastar Pharmaceuticals from a “b-” rating to a “c” rating in a report on Friday, August 7th. Northland Securities raised Amphastar Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $24.00 price target on the stock in a report on Monday, October 5th. Finally, Zacks Investment Research cut Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, November 9th. Five research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. Amphastar Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $22.67.

NASDAQ:AMPH opened at $18.36 on Friday. The firm has a market cap of $872.17 million, a P/E ratio of 131.14 and a beta of 1.02. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.73 and a current ratio of 2.86. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $12.32 and a fifty-two week high of $22.69. The firm has a 50-day simple moving average of $20.05 and a two-hundred day simple moving average of $19.91.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings results on Wednesday, November 11th. The company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.01. Amphastar Pharmaceuticals had a net margin of 1.97% and a return on equity of 5.50%. On average, equities research analysts predict that Amphastar Pharmaceuticals, Inc. will post 0.38 EPS for the current year.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API.

Featured Article: What are earnings reports?

Want to see what other hedge funds are holding AMPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH).

Institutional Ownership by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.